Powder: -20°C for 3 years
In solvent: -80°C for 2 years
KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM.
Description | KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM. |
In vitro | KA2507 did not inhibit the in vitro proliferation of mouse or human cancer cells at concentrations that are selective for HDAC6 inhibition. |
In vivo | KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model. KA2507 also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models. Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I. KA2507 exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg).[1] |
Synonyms | KA-2507 |
Molecular Weight | 322.32 |
Formula | C16H14N6O2 |
CAS No. | 1636894-46-6 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 60 mg/mL (186.15 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.